Pathogenesis of Psoriatic Arthritis: A Broader Understanding to Inform Next Steps


Guru Sonpavde, MD
Bladder Cancer Director Dana Farber Cancer Institute
Associate Professor of Medicine Harvard Medical School Boston, MA
Guru Sonpavde, MD

Guru P. Sonpavde, MD, is a medical oncologist and the Bladder Cancer Director at the Dana Farber Cancer Institute as well as Associate Professor of Medicine at Harvard Medical School. At Dana-Farber, he leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to cure bladder cancer. He is the national or international Principal Investigator of multiple clinical trials for patients with bladder cancer. Dr. Sonpavde has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and Bladder Cancer Task Force of the U.S. NCI GU Steering Committee.

Anthony Fernandez, MD, PhD
Director of Medical Dermatology
W.D. Steck Chair of Clinical Dermatology Departments of Dermatology and Pathology
Dermatology and Plastic Surgery Institute Cleveland Clinic Cleveland, OH
Anthony Fernandez, MD, PhD

Anthony P. Fernandez, MD, PhD, completed his dermatology residency at the University of Miami, Florida and a dermatopathology fellowship at the Cleveland Clinic. He is currently a staff physician at the Cleveland Clinic in Cleveland, Ohio where he practices both medical dermatology and dermatopathology and serves as Director of medical dermatology and the W.D. Steck Chair of Clinical Dermatology. He is also Co-Medical Director of Continuing Medical Education at the Cleveland Clinic and Assistant Professor of Clinical Medicine at the Cleveland Clinic Lerner College of Medicine.

Clinically, Dr. Fernandez specializes in treatment of systemic autoimmune and inflammatory diseases with prominent cutaneous involvement. His research interests mirror his clinical interests, with ongoing projects involving psoriasis, dermatomyositis, lupus erythematosus, cutaneous vasculitis, and pemphigus vulgaris. He is also active in a variety of national professional organizations, such as the American Academy of Dermatology, the Americans Society of Dermatopathology, and the Rheumatologic Dermatology Society. Dr. Fernandez is currently an Associate Editor for the Journal of the American Academy of Dermatology and a member of Healio’s Dermatology and Psoriasis Peer Perspective Boards.

Statement of Need

Psoriatic arthritis (PsA) presents in up to 30% of patients with psoriasis (PsO) and may precede, occur concurrently with, or occur after the development of PsO. It is imperative to recognize that PsA can present in the dermatology or rheumatology clinic depending on the primary symptom and that clinicians then accurately diagnose PsA by utilizing screening questionnaires, as well as screening patients with PsA for common comorbidities.

The first episode of this CME Outfitters Snack series on the evolving treatment landscape for PsA features expert faculty describing clinically relevant pathophysiologic processes that contribute to the development of psoriatic arthritis in order to facilitate proper screening and faster diagnosis of patients with PsA.

Learning Objectives

At the end of this CME/CE activity, participants should be able to describe clinically relevant pathophysiologic processes that contribute to the development of psoriatic arthritis.

Financial Support

Supported by an educational grant from Bristol Myers Squibb Company.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Fernandez reports that he receives grants from Mallinckrodt and Novartis. He receives research support from AbbVie Inc.; Corbus Pharmaceuticals Holdings, Inc.; Mallinckrodt Pharmaceuticals; and Pfizer Inc. He is on the speakers bureau for AbbVie Inc.; Mallinckrodt Pharmaceuticals; and Novartis. He is a consultant for AbbVie Inc.; Alexion Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Mallinckrodt Pharmaceuticals; and Novartis.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Michael J. Franks, MSN, AGACNP-BC, FNP, BC (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-029-H01-P





Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.




Pathogenesis of Psoriatic Arthritis: A Broader Understanding to Inform Next Steps
Event Date: 01/16/2021